Hereditary fructose intolerance (HFI) is an autosomal recessive metabolic disorder caused by aldolase (fructose-1,6-bisphosphate aldolase, EC 4.1.2.13) B deficiency. The B isoform of aldolase is critical for the metabolism of exogenous fructose by the liver, kidney, and intestine, since it can use fructose-1-phosphate as substrate at physiological concentrations, unlike aldolases A and C. Affected subjects suffer abdominal pain, vomiting, and hypoglycaemia after the ingestion of fructose, sucrose, or sorbitol. Continued ingestion of noxious sugars causes hepatic and renal injury, which eventually leads to liver cirrhosis and sometimes death, particularly in small infants. Treatment consists of strict elimination of fructose, sucrose, and sorbitol from the diet immediately after HFI is suspected. This diet exclusion therapy allows for a rapid recovery and, if liver and kidney damage is not irreversible, an uneventful course thereafter. Confirmatory diagnosis is generally made by intravenous fructose tolerance tests and assays of aldolase B activity in hepatic biopsies.

Since the gene coding for human aldolase B (ALDOB) was cloned, at least 22 different mutations associated with HFI have been described. Kinetic analyses of recombinant aldolase B mutants and molecular modelling studies have shown important structure-function implications for several aldolase B residues affected by HFI mutations. The first HFI mutation identified, termed A149P, is a G→C transversion at the first base of codon 149, which replaces the normal alanine by a proline residue. This missense mutation accounts for more than 50% of mutant alleles in HFI patients from different populations worldwide; the frequency of heterozygous carriers in the United Kingdom has been estimated to be 1.32 ± 0.49%, which allows the prediction of an incidence of HFI associated with the A149P allele of 1 in 23 000 births. The three more common aldolase B mutations, A149P, A174D, and N334K, account for more than 80% of HFI alleles in populations from European countries. Although there are many reports dealing with the identification of aldolase B mutations associated with HFI in different European populations, studies on the incidence of these mutations in Spanish subjects have not been reported.

In this work, we have analysed the molecular defects in the ALDOB gene in 28 HFI patients from Spain. For this purpose, we have performed PCR amplification of the aldolase B coding exons from the probands and subsequent analysis by restriction endonuclease digestion, allele specific oligonucleotide (ASO) hybridisation, and direct sequencing. Our results have allowed us to estimate the frequencies of HFI alleles in Spanish patients, as well as to discover two novel mutations in the ALDOB gene (g.4271C>G and g.1133G>A) that can cause HFI.

MATERIALS AND METHODS

Subjects
Twenty-eight HFI patients from 21 independent families, referred by hospitals in Spain, were studied. Proband were resident in the following regions: Madrid (11 families), Andalucía (4), Galicia (3), Extremadura (1), Valencia (1), and Spanish possessions in North Africa (1). HFI diagnosis was based on enzymatic studies (deficient aldolase B activity in hepatic biopsies from 16 patients) or clinical symptoms (six patients). Another six subjects were suspected to suffer from HFI on the basis of dietary intolerance with episodes suggestive of hypoglycaemia and occurrence of the disease in their first degree relatives.

Reagents
Thermostable DNA polymerase, deoxynucleotides, and general PCR products were from Biotools (Madrid, Spain). Agarose and acrylamide were purchased from Bio-Rad (Mannheim, Germany). [α-32P]dCTP and [γ-32P]ATP were obtained from American Radiolabeled Chemicals (St Louis, Missouri).
MO, USA), and [α-32P]dATP was from Nuclear Iberica (Madrid, Spain). Reagents for reverse transcription were purchased from Applied Biosystems (Madrid, Spain). The remaining reagents were from Roche (Barcelona, Spain), Sigma (Madrid, Spain), or Merck (Barcelona, Spain).

Genomic DNA analysis

Genomic DNA was prepared from peripheral blood samples (1-2 ml) or from hepatic biopsies (about 10 mg) by standard Genomic DNA analysis. Remaining reagents were from Roche (Barcelona, Spain), chased from Applied Biosystems (Madrid, Spain). The reagents for reverse transcription were purified in a solution containing 6 × SSC (0.09 mol/l sodium citrate and 0.9 mol/l Na Cl), 0.1% polyvinylpyrrolidone, and 0.1% bovine serum albumin), and 100 µg/ml denatured salmon sperm DNA for two hours at 65°C. They were then hybridised overnight at 37°C by the addition of 100 ng of allele specific oligonucleotide probes, previously labelled at their 5’ ends with 50 µCi [γ-32P]ATP and polynucleotide kinase, to the pre-hybridisation solution. The sequences of the probes used were: wild type, 5’-TCGCTACGCCAGCATCT-3’; A174D, 5’-AGATGCTGTCGTAAGCGA-3’. Blots were washed three times in 6 × SSC, 0.1% sodium dodecyl sulphate for 10 minutes at room temperature, and then twice in 6 × SSC, 0.01% sodium dodecyl sulphate at 54°C for two minutes (high stringency wash). Blots were then exposed to x ray films for autoradiography.

The presence of the ΔE4 mutation was confirmed by ASO hybridisation of exon 4 fragments.16 PCR amplified from genomic DNA with oligonucleotides E4+ and E4- as primers. Conditions for sample transfer to nylon membranes, prehybridisation, hybridisation, oligonucleotide labelling, and membrane washes were as described above for the detection of the A174D mutation, with the exception that the high stringency wash was made in 6 × SSC, 0.1% sodium dodecyl sulphate for two minutes at 63°C.17 Oligonucleotide probes were: wild type, 5’-GCGAGGACAGAAGAAGAAGAC-3’, ΔE4, 5’-GCGAGGACAGAAGAAGAAGAC-3’. The presence of the N334K mutation was analysed by amplification of a 299 bp DNA fragment by PCR, using oligonucleotides A9+ and A9- as primers, and digestion with the restriction endonuclease Ddel. Wild type DNA fragments were excised into two digestion products of 241 and 58 bp. The N334K introduces an additional Ddel target site at the site of the mutation (CTAG), so that digestion of the mutant fragments is expected to render three products of 141, 100, and 58 bp.

To confirm the occurrence of the mutations detected by the methods described above, as well as to carry out a screening for additional mutant aldolase B alleles, direct sequence determination of PCR products corresponding to exons 2-9 was performed, by the chain terminators method (fmol kit, Promega), following the instructions of the manufacturer. The g.4271C>G mutation was further assessed by PCR amplification of a 230 bp fragment enclosing exon 6, which was subjected to digestion with the restriction endonuclease BanI. The mutation destroys a target site for this enzyme (GGTACC); BanI digestion of wild type PCR products is expected to render two fragments of 142 and 88 bp, while the mutant ones should not be excised by the endonuclease.

In most cases (14 of 21 families), availability of blood samples from patients’ relatives allowed us to follow the segregation of the aldolase B alleles. Southern blot analysis was also performed in genomic DNA samples from four probands who appeared to be homozygous for a mutant aldolase B allele and whose parents’ samples were not available. For this purpose, genomic DNA was digested with EcoRI, electrophoresed on a 0.8% agarose gel, and blotted onto nylon membranes by standard laboratory techniques.18 The nylon membranes were hybridised with a human aldolase B cDNA probe (nucleotides -37 to 1173) previously labelled by random priming with [α-32P]dCTP and then exposed to x ray films for autoradiography.
cDNA analysis

Total RNA was obtained from hepatic biopsy samples by the single step method. This RNA was used as template to prepare total liver cDNA by reverse transcription in the presence of random hexanucleotides as primers (GeneAmp Gold RNA PCR kit, Applied Biosystems), following the instructions of the manufacturer. Several DNA fragments corresponding to the sequence of the human aldolase B cDNA were amplified by PCR from total liver cDNA. Thirty PCR cycles were performed at the following reaction conditions: denaturation at 94°C for 45 seconds, annealing at 58°C for 45 seconds, and extension at 72°C for 45 seconds. A final elongation was carried out at 72°C for five minutes. DNA fragments comprising nucleotides –82 to 1214 of human aldolase B cDNA were amplified using the following primers: forward, 5' ′-ATCTGTCTTATTTGGCAGCTG-3' and reverse, 5' ′-GTGTTGTATTTCCAGCAGTTC-3'. Segments corresponding to nucleotides –37 to 1173 of aldolase B cDNA were subcloned into the EcoRV and EcoRI sites of pBluescript II (Stratagene) by standard laboratory techniques. The resulting plasmid constructs were sequenced. In another series of experiments, DNA fragments corresponding to positions 250 to 553 of aldolase B cDNA were amplified by PCR from total liver cDNA, using the following primers: forward, 5'-CTCTACCAGAAGGACAGC-3' and reverse, 5'-GTACCAGTCCATTCTGCF-3'. PCR products were resolved by electrophoresis on 6% polyacrylamide gels and visualised by ethidium bromide staining. Some PCR reactions were carried out in the presence of 10 µCi [α-32P]dCTP and the products were resolved by polyacrylamide gel electrophoresis and visualised by autoradiography. Radioactivity incorporated into the PCR products was quantitated with an InstantImager apparatus (Packard BioScience Company, Meriden, CT, USA).

Biochemical assays

Aldolase activity in hepatic biopsies was assayed as described by Blostein and Rutter, using 10 mmol/l fructose-1-phosphate or 2.5 mmol/l fructose-1,6-bisphosphate as substrates. Liver samples from unaffected subjects served as controls. One enzymatic unit (U) is the amount of enzyme that catalyses the conversion of 1 µmol substrate per minute. Protein was measured by the method of Lowry et al using bovine serum albumin as standard.

Statistical analysis

The 95% confidence limits for allele frequencies in the population sample were derived from values obtained assuming a binomial distribution. The parameter “p” was estimated as the sum of frequencies of A149P, Δ4E4, and A174D alleles. Hence, the probability that a HFI patient harbours these alleles is p for two alleles and 2pq for one allele, while the probability of

Figure 1

Detection of common mutations in the ALDOB gene. Several DNA fragments corresponding to the coding exons of the ALDOB gene were amplified by PCR. Then, PCR products were subjected to restriction endonuclease digestion or ASO hybridisation as described. (A) Detection of the A149P mutation in family F7 by endonuclease digestion. Arrows indicate the positions of diagnostic bands of 214, 151, and 63 bp after agarose gel electrophoresis. F7.1, F7.2, and F7.3 are A149P heterozygotes and F7.4 an A149P homozygote. C+, positive control. (B) Detection of the A174D mutation in families F3 and F17 by ASO hybridisation. WT, A174D, membranes hybridised with the wild type or the mutant oligonucleotide, respectively. F3.1 and F17.2 are wild type homozygotes; F3.2, F3.3, F3.4, F17.1, and F17.3, A174D heterozygotes. The dashed symbol represents a subject who was not tested. C−, negative control. Cwt, Cmut, positive controls for the wild type and A174D alleles, respectively. (C) Detection of the N334K mutation in patient 468 by endonuclease digestion. Arrows indicate the positions of diagnostic bands of 241, 141, and 100 bp after agarose gel electrophoresis. An additional expected band of 58 bp is not evident in this picture. 468, N334K heterozygous patient; C, unaffected control. (D) Detection of the Δ4E4 mutation in families F1 and F5 by ASO hybridisation. WT, Δ4E4, membranes hybridised with the wild type or the mutant oligonucleotide, respectively. F1.1 is a wild type homozygote; F1.2, F1.3, F1.4, F5.1, and F5.2, Δ4E4 heterozygotes; F5.3, Δ4E4 homozygote.
having two mutant alleles other than A149P, Δ4E4, or A174D is q (where q = 1 - p).

RESULTS

Screening for common ALDOB gene mutations in HFI patients

We investigated the presence of mutations in the ALDOB gene associated with HFI in Spanish patients. First, a molecular analysis to search for the three major mutations in European HFI populations, A149P, A174D, and N334K,1 was performed using restriction digestion or ASO hybridisation. Fig 1A, B, and C shows examples of the detection of these mutant alleles in several HFI families. As a result of this screening, 11 patients were found to be A149P homozygotes and another 15 patients carried a single copy of the A149P allele. Among the latter, there were two A149P/A174D and one A149P/N334K compound heterozygotes. Another patient was found to be homozygous for the A174D mutation. The individual aldolase B genotypes of all patients studied is shown in table 2.

The presence of another widespread HFI allele, A174D, was analysed by DNA sequencing and ASO hybridisation (fig 1D). This allele was found in patients from six families; one patient was found to be a A149P/Δ4E4 homozygote and nine were Δ4E4/Δ4E4 compound heterozygotes (table 2).

In four patients (210, 476, 663, and 717) who appeared to be compound heterozygotes, another patient was found to be homozygous for either the A149P or the A174D mutations (table 2), the mutant aldolase B alleles could not be traced back because samples from their parents were not available. To test the presence of large deletions or rearrangements in aldolase B alleles, genomic DNA from these patients and from an unaffected control was subjected to Southern blot analysis. Thus, EcoRI digested genomic DNA was hybridised to an aldolase B cDNA probe; in all cases, only the two expected bands of sizes about 5.8 and 8.5 kb21 were detected (not shown).

Screening for other ALDOB gene mutations in HFI patients

Further screening of less common or unknown HFI alleles by direct sequencing of PCR products corresponding to the coding exons plus intron-exon boundaries of the ALDOB gene led us to the identification of two novel sequence variations associated with HFI, designated g.4271C>G and g.1133G>A following the recommendations for mutation nomenclature compiled by Antonarakis et al.22 The g.4271C>G mutation is a C→G transversion of the second base of codon 184 in exon 6, which is inferred to replace the normal proline with an arginine residue in the aldolase B protein. Thus, we propose P184R as a trivial name for this sequence variation. The mutation was found by direct sequencing of exon 6 in DNA from two subjects from a single family (not shown), who were suspected of having HFI on the basis of dietary intolerance and clinical evaluation. The g.4271C>G mutation eliminates a BanI restriction site (GGTACC), which allowed mutation detection by restriction analysis to follow the segregation of the mutant allele in the probands' family (fig 2). The two HFI patients (F11.3 and F11.5) were A149P/g.4271C>G compound heterozygotes (table 2).

The g.1133G>A mutation was found by direct sequencing of aldolase B exons (fig 3), in a single allele of an HFI patient, named 529, whose hepatic aldolase B deficiency was shown by enzymatic assays. The other HFI allele in this subject was named 529, whose hepatic aldolase B deficiency was shown by enzymatic assays. Another patient was found to be homozygous for the A174D mutation. The individual aldolase B genotypes of all patients studied is shown in table 2.

The two aldolase B alleles in each subject are indicated. Novel alleles are in bold. Aldolase activity towards fructose-1-phosphate (F-1-P) and fructose-1,6-bisphosphate (F-1,6-P2) was assayed in hepatic biopsies, where available, as indicated in Materials and methods. ND, not determined.

Table 2 Genotypes and hepatic aldolase activities of HFI patients

<table>
<thead>
<tr>
<th>Family</th>
<th>Proband</th>
<th>Genotype</th>
<th>Aldolase activity (mU/mg protein)</th>
<th>F-1-P/F-1,6-P2 activity ratio</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td>F-1-P</td>
<td>F-1,6-P2</td>
</tr>
<tr>
<td>F1</td>
<td>F1.3</td>
<td>A149P/Δ4E4</td>
<td>ND</td>
<td>ND</td>
</tr>
<tr>
<td>F1</td>
<td>F1.4</td>
<td>A149P/Δ4E4</td>
<td>ND</td>
<td>ND</td>
</tr>
<tr>
<td>F2</td>
<td>F2.9</td>
<td>A149P/A149P</td>
<td>1.8</td>
<td>10.7</td>
</tr>
<tr>
<td>F3</td>
<td>F3.4</td>
<td>A149P/A174D</td>
<td>ND</td>
<td>ND</td>
</tr>
<tr>
<td>F5</td>
<td>F5.3</td>
<td>Δ4E4/Δ4E4</td>
<td>&lt;1.0</td>
<td>6.8</td>
</tr>
<tr>
<td>F6</td>
<td>F6.2</td>
<td>A149P/A149P</td>
<td>2.6</td>
<td>4.8</td>
</tr>
<tr>
<td>F7</td>
<td>F7.4</td>
<td>A149P/A149P</td>
<td>2.7</td>
<td>9.4</td>
</tr>
<tr>
<td>F8</td>
<td>F8.3</td>
<td>A149P/Δ4E4</td>
<td>1.4</td>
<td>5.4</td>
</tr>
<tr>
<td>F11</td>
<td>F11.3</td>
<td>A149P/g.4271C&gt;G</td>
<td>ND</td>
<td>ND</td>
</tr>
<tr>
<td>F11</td>
<td>F11.5</td>
<td>A149P/g.4271C&gt;G</td>
<td>ND</td>
<td>ND</td>
</tr>
<tr>
<td>F12</td>
<td>F12.3</td>
<td>A149P/A149P</td>
<td>ND</td>
<td>ND</td>
</tr>
<tr>
<td>F13</td>
<td>F13.4</td>
<td>A149P/A149P</td>
<td>2.5</td>
<td>8.4</td>
</tr>
<tr>
<td>F16</td>
<td>F16.3</td>
<td>A149P/Δ4E4</td>
<td>ND</td>
<td>ND</td>
</tr>
<tr>
<td>F16</td>
<td>F16.4</td>
<td>A149P/Δ4E4</td>
<td>ND</td>
<td>ND</td>
</tr>
<tr>
<td>F17</td>
<td>F17.3</td>
<td>A149P/A174D</td>
<td>1.1</td>
<td>10.3</td>
</tr>
<tr>
<td>F18</td>
<td>F18.1</td>
<td>A149P/Δ4E4</td>
<td>ND</td>
<td>ND</td>
</tr>
<tr>
<td>F18</td>
<td>F18.3</td>
<td>A149P/Δ4E4</td>
<td>2.2</td>
<td>11.9</td>
</tr>
<tr>
<td>F18</td>
<td>F18.4</td>
<td>A149P/Δ4E4</td>
<td>ND</td>
<td>ND</td>
</tr>
<tr>
<td>F19</td>
<td>F19.1</td>
<td>A149P/Δ4E4</td>
<td>ND</td>
<td>ND</td>
</tr>
<tr>
<td>F19</td>
<td>F19.4</td>
<td>A149P/Δ4E4</td>
<td>&lt;1.0</td>
<td>7.4</td>
</tr>
<tr>
<td>71F</td>
<td>71</td>
<td>A149P/Δ4E4</td>
<td>&lt;1.0</td>
<td>2.6</td>
</tr>
<tr>
<td>210F</td>
<td>210</td>
<td>A149P/Δ4E4</td>
<td>1.5</td>
<td>7.8</td>
</tr>
<tr>
<td>468F</td>
<td>468</td>
<td>A149P/N334K</td>
<td>&lt;1.0</td>
<td>12.2</td>
</tr>
<tr>
<td>476F</td>
<td>476</td>
<td>A174D/A174D</td>
<td>&lt;1.0</td>
<td>10.2</td>
</tr>
<tr>
<td>529F</td>
<td>529</td>
<td>A149P/g.1133G&gt;A</td>
<td>&lt;1.0</td>
<td>1.8</td>
</tr>
<tr>
<td>663F</td>
<td>663</td>
<td>A149P/Δ4E4</td>
<td>3.0</td>
<td>7.3</td>
</tr>
<tr>
<td>717F</td>
<td>717</td>
<td>A149P/Δ4E4</td>
<td>&lt;1.0</td>
<td>5.5</td>
</tr>
</tbody>
</table>

The two aldolase B alleles in each subject are indicated. Novel alleles are in bold. Aldolase activity towards fructose-1-phosphate (F-1-P) and fructose-1,6-bisphosphate (F-1,6-P2) was assayed in hepatic biopsies, where available, as indicated in Materials and methods. ND, not determined.

The mean aldolase activity (mU/mg protein) for 21 patients was 22.4 (SD 8.0) with activity ratios of 2.6 (SD 0.3).
In order to characterise better the effects of the g.1133G>A mutation on aldolase B cDNA, fragments corresponding to nucleotides 250 to 553 of aldolase B cDNA (E3-6 fragments), containing part of exon 3, exons 4 and 5, and part of exon 6 sequences, were amplified from either total liver cDNA or from pA149P or pA149WT plasmids, and resolved by non-denaturing polyacrylamide gel electrophoresis. PCR from total cDNA from patient 529 yielded two products which migrated as separate bands under polyacrylamide gel electrophoresis (not shown). The upper band corresponded to the full length, 304 bp fragment, which was also the only band observed when amplification was carried out with either total cDNA from a control subject or pA149P DNA as templates. The lower band corresponded to the deleted form of aldolase B cDNA E3-6 fragments, 292 bp in length, which was the only PCR product obtained by amplification from pA149WT. We analysed 39 independent plasmids containing aldolase B cDNA from patient 529 of which 14 corresponded to the pA149WT type as determined by BadHI digestion. Amplification of E3-6 fragments by PCR from pA149WT plasmids only yielded the shorter, 12 nucleotide deleted form of the aldolase B cDNA fragment (not shown).

Finally, we performed the amplification of E3-6 fragments from total cDNA from patient 529 in the presence of [α-32P]dCTP in an attempt to estimate the relative amounts of the two aldolase B cDNA fragments. As shown in fig 5, radioactive incorporation into the two PCR products was exponential for 19 to 24 cycles; the efficiency factor (R) calculated as indicated by Chelly et al17 was 0.70 and 0.72 for amplification of the 292 and 304 bp fragments, respectively. However, the radioactivity incorporated into the 292 bp fragment appeared to be reduced by 36-44% in comparison to that determined for the 304 bp fragment (fig 5B), thus indicating that there was a reduced amount of the 12 nucleotide deleted fragment.

Aldolase activity in samples from HFI patients

We also measured aldolase activity in hepatic biopsies from HFI patients where they were available for diagnosis by enzymatic assays. As previously established,1 in all HFI samples analysed, aldolase activities against fructose-1-phosphate were lower than 15% of the mean activities in control biopsies, and the ratios between aldolase activities against fructose-1-phosphate and fructose-1,6-bisphosphate were higher than 1.7 in patients, while those of control subjects were 1.1 (SD 0.3) (table 2). However, both the specific activities against fructose-1-phosphate and the ratios of activity against the two aldolase substrates varied broadly within a single genotype (for example, among A149P homozygotes). Hence, these
results did not allow us to establish a correlation between genotypes and residual aldolase B activities.

Mutation frequencies
The distribution of allele frequencies among the independent families studied is shown in table 3. The prevalent A149P mutation was present in 29 of 43 independent HFI alleles (one family had three probands with three independently segregating alleles), thus giving a frequency of 67.4%, which was very similar to those reported in pan-European populations,\(^1\)\(^2\)\(^4\) but higher than that reported (29%) in HFI patients from Italy.\(^2\)\(^6\) The frequency of the \(\Delta\)4E4 mutation, 16.3%, was much higher than its world wide frequency as reported by Tolan,\(^3\) but quite similar to that found in Italy (18.5%).\(^2\)\(^6\) The A174D and N334K mutations had frequencies somewhat lower than those reported in either pan-European or world wide population studies.\(^1\)\(^1\)\(^4\)\(^4\)

Regarding the distribution of HFI alleles and genotypes found in this study, it is worth noting that all the HFI patients analysed had at least one A149P, \(\Delta\)4E4, or A174D allele (table 2). Assuming a binomial distribution for these common alleles, it can be estimated that 93.0 ± 7.6% (95% confidence limits) of the independent HFI alleles would be accounted for by A149P, \(\Delta\)4E4, and A174D. At the lower limit, therefore, 97.8% of HFI patients (0.854 + (2 × 0.854 × 0.146)) would be expected to carry at least one of these three alleles, and only 2.2% would carry two mutant alleles different from A149P, \(\Delta\)4E4, or A174D. These estimations are close to the results of this survey, in which the actual frequency of HFI patients carrying at least one copy of these three alleles reached 100%.

DISCUSSION
The aim of this work was to investigate the mutations in the ALDOB gene associated with HFI in a population sample of 28 patients from 21 independent families, referred by several hospitals in Spain. With the aid of PCR amplification of aldolase B exons and conventional molecular biology techniques, we have identified the HFI mutations present in all patients. Four mutations (A149P, A174D, \(\Delta\)4E4, and N334K) have been previously described in other studies and are considered widespread, relatively frequent mutations.\(^1\)\(^4\) In addition, we have found two novel HFI alleles, termed g.4271C>G and g.1133G>A, each present in one gene copy in patients from different families.
The g.4271C>G mutation changes the sequence at codon 184 from CCT to CGT, and therefore is deduced to replace a proline residue with an arginine at position 184 of the aldolase B protein. This would be a non-conservative substitution of a residue which is conserved in eukaryotic aldolases and located in the vicinity of other conserved residues involved in active site formation, such as Ile-185, Glu-187, and Glu-189. These facts strongly support that the g.4271C>G mutation can cause aldolase B deficiency. However, in the absence of hepatic aldolase activity determinations in the affected patients, assessment of the effects caused by the g.4271C>G mutation on enzyme activity would require further studies.

In agreement with this, we found that the g.1133G>A mutation provoked a deletion of the last 12 nucleotides of exon 3 from aldolase B cDNA. A reasonable explanation for this deletion is that the point mutation at the splice site would allow the use of an alternative, cryptic 5' splice site located 12 nucleotides upstream from the normal site by the splicing machinery; actually, a GT sequence is located in the ALDOB gene just at the 5' end of the deleted sequence, and is preceded by a G at the −1 position as is the GT invariant dinucleotide in the normal 5' splice site of intron 3 of the g.1133G>A mutation. This hypothesis is in agreement with the concept that most cryptic sites activated by mutations in splice sites are located around 40% in the quantity of the 12 nucleotide deleted cDNA fragment, in comparison with that of the normal length fragment. This finding suggests that the g.1133G>A mutation could provoke a reduction in the levels of mature aldolase B mRNA. In connection with this, a G to A mutation at position −1 of the 5' splice site of intron 5 of the gene encoding β-hexosaminidase α subunit causes both the skipping of the mutated exon and a 90% reduction in the levels of β-hexosaminidase α mRNA. Furthermore, mutations in the β-globin gene that reduce the efficiency of pre-mRNA splicing cause the degradation and/or retention of unprocessed transcripts in the nucleus. Thus, it is conceivable that the g.1133G>A mutation, besides promoting the use of a cryptic splice site, may impair the efficiency of splicing of mRNA precursors and therefore give rise to deficiently processed transcripts that are degraded in the nucleus.

In addition to the genetic analysis, aldolase activity assays were performed in a number of liver samples from HFI patients. They confirmed aldolase B deficiency in all cases assayed regardless of individual genotypes. However, we could not find a close relationship between mutated aldolase B alleles and residual enzyme activities in hepatic biopsies; this was because of considerable variability in both specific aldolase B activities and aldolase activity ratios among patients with the same HFI genotypes and because for most of these genotypes there was a single biopsy determination.

The first study of the genetics of HFI in a population sample of Spanish patients. The allele frequencies found have been compared with those previously reported in pan-European studies, supporting the concept that this mutation arose early during the evolution of modern populations. The A174D and N334K mutations, which are relatively common in European HFI patients, reached low frequencies in our patient population. These results are in agreement with the geographical distribution of HFI mutations proposed by several authors, who suggest that the A149P mutation is widely distributed among European populations, while the N334K allele occurs mainly in central and eastern Europe, and the A174D allele in central and southern European locations. The relatively high incidence of the Δ4E4 mutation (16% of HFI alleles) is noteworthy, comparable to that observed in Italian HFI patients. Thus, it appears that this allele is more abundant in southern Europe. It is worth mentioning that the P184R mutation, reported here for the first time, was found in a Spanish family from the Spanish territories in North Africa. Thus, P184R may represent a geographically restricted ("private") mutation and/or a relatively frequent HFI allele in populations from North Africa, but further data are needed to support this speculation.

The distribution of HFI alleles among the patients studied in this work indicates that 93.0 ± 7.6% of independent alleles would be accounted for by A149P, Δ4E4, and A174D, assuming that the presence of these alleles in HFI patients follows a binomial distribution. Moreover, at the lower confidence limit, 97.8% of the patients would be expected to carry at least one copy of these three alleles. Therefore, analysis of the presence of these mutations in Spanish subjects suspected of having HFI could be of considerable diagnostic relevance. In this sense, some authors have adopted a protocol for the genetic diagnosis of HFI that, in view of our results, could be applied with some modifications for genetic diagnosis of HFI in Spain. Thus, an initial screening for the presence of A149P, A174D, Δ4E4, and N334K mutations by restriction endonuclease digestion and ASO hybridisation would be carried out; identification of any of these mutant alleles in at least a single copy in a symptomatic patient would be indicative of HFI. Then, if the other allele were different, direct sequencing of aldolase B exons and exon/intron boundaries would be performed to identify the second allele and confirm HFI diagnosis. Subjects not having any of the four common mutant alleles, and if their parents were not related, would be studied further only if a positive clinical or enzymatic test had been obtained.

### Table 3: Allele frequencies in 21 independent Spanish HFI families

<table>
<thead>
<tr>
<th>Mutation</th>
<th>No of alleles</th>
<th>Frequency (%)</th>
<th>Reported frequency (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>A149P</td>
<td>29</td>
<td>67.4</td>
<td>61.0*</td>
</tr>
<tr>
<td>Δ4E4</td>
<td>7</td>
<td>16.3</td>
<td>8.1</td>
</tr>
<tr>
<td>A174D</td>
<td>4</td>
<td>9.3</td>
<td>15.8*</td>
</tr>
<tr>
<td>N334K</td>
<td>1</td>
<td>2.3</td>
<td>7.2*</td>
</tr>
<tr>
<td>g.1133G&gt;A</td>
<td>1</td>
<td>2.3</td>
<td></td>
</tr>
<tr>
<td>g.4271C&gt;G</td>
<td>1</td>
<td>2.3</td>
<td></td>
</tr>
<tr>
<td>Total</td>
<td>43</td>
<td>100</td>
<td></td>
</tr>
</tbody>
</table>

The number of independently segregating HFI alleles and their frequencies are indicated. One family had three probands with three independent mutant alleles. Reported frequencies are those described by Cox in a pan-European population sample or Tolain in a compendium of studies worldwide.

The g.1133G>A mutation is a single G to A transition in the last nucleotide of exon 3, which does not change the sense of the affected codon. Nevertheless, the changed nucleotide is located at the −1 position of the 5' splice site of intron 3 of the ALDOB gene. At least 10 identical nucleotide changes have been shown to cause abnormal RNA splicing in different mammalian genes. In addition, many of these sequence variations have been associated with hereditary human diseases. In agreement with this, we found that the g.1133G>A mutation provoked a deletion of the last 12 nucleotides of exon 3 from aldolase B cDNA. A reasonable explanation for this deletion is that the point mutation at the splice site would allow the use of an alternative, cryptic 5' splice site located 12 nucleotides upstream from the normal site by the splicing machinery; actually, a GT sequence is located in the ALDOB gene just at the 5' end of the deleted sequence, and is preceded by a G at the −1 position as is the GT invariant dinucleotide in the normal 5' splice site of intron 3. This hypothesis is in agreement with the concept that most cryptic sites activated by mutations in splice sites are located within 100 nucleotides from the authentic site. In addition, we were not able to detect any aldolase B cDNA fragment of normal length derived from the g.1133G>A allele, which suggests that missplicing is present in at least a large majority of mRNA molecules transcribed from this aldolase B allele in the liver sample from the patient. The mutated aldolase B mRNA originating from the g.1133G>A allele should be translated into a protein in which four amino acids (residues 104-107) have been eliminated, while the remainder of the protein sequence is kept intact. This modification at the protein level could alter the stability and/or the catalytic properties of the enzyme and thus contribute to the HFI phenotype, but further studies are needed to test this possibility.

By assaying the incorporation of radioactivity from [α-32P]dCTP into aldolase B cDNA products amplified from patient's total cDNA, we observed an apparent reduction of around 40% in the quantity of the 12 nucleotide deleted cDNA fragment, in comparison with that of the normal length fragment. This finding suggests that the g.1133G>A mutation could provoke a reduction in the levels of mature aldolase B mRNA. In connection with this, a G to A mutation at position −1 of the 5' splice site of intron 5 of the gene encoding β-hexosaminidase α subunit causes both the skipping of the mutated exon and a 90% reduction in the levels of β-hexosaminidase α mRNA. Furthermore, mutations in the β-globin gene that reduce the efficiency of pre-mRNA splicing cause the degradation and/or retention of unprocessed transcripts in the nucleus. Thus, it is conceivable that the g.1133G>A mutation, besides promoting the use of a cryptic splice site, may impair the efficiency of splicing of mRNA precursors and therefore give rise to deficiently processed transcripts that are degraded in the nucleus.
previously. In the event of consanguinity between the proband’s parents, then clinical symptoms should indicate the need to perform a search for the mutant aldolase B allele(s) by direct sequencing. It must be stressed that, in contrast to other tests applied for confirmation of HFI diagnosis, genetic analysis allows for both confirmatory diagnosis and genetic counselling with little discomfort to the probands, since it only requires a small sample of peripheral blood.

ACKNOWLEDGEMENTS

This work was supported by “Fondo de Investigación Sanitaria” (grants No 96/2030 and 01/0225), Spanish Ministry of Health. JCS-G is funded by the programme “Contratos de Investigadores en el Sistema Nacional de Salud”, FIS, Spanish Ministry of Health. Critical reading of the manuscript by JG Castaño and RG Garces is gratefully acknowledged.

Authors’ affiliations

J C Sánchez-Gutiérrez, T Benlloch, M A Leal, B Samper, J García-Ripoll, J E Feliu, Servicio de Endocrinología Experimental, Hospital Universitario Clínica Puerta de Hierro and Departamento de Bioquímica, Facultad de Medicina, Universidad Autónoma de Madrid, Madrid, Spain

Correspondence to: Dr J C Sánchez-Gutiérrez, Servicio de Endocrinología Experimental, Hospital Universitario Clínica Puerta de Hierro, San Martín de Porres 4, 28035 Madrid, Spain; juliocesar.sanchez@uam.es

REFERENCES

Molecular analysis of the aldolase B gene in patients with hereditary fructose intolerance from Spain

J C Sánchez-Gutiérrez, T Benlloch, M A Leal, B Samper, I García-Ripoll and J E Felìu

doi: 10.1136/jmg.39.9.e56

Updated information and services can be found at:
http://jmg.bmj.com/content/39/9/e56

These include:

References
This article cites 29 articles, 11 of which you can access for free at:
http://jmg.bmj.com/content/39/9/e56#BIBL

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Topic Collections
Articles on similar topics can be found in the following collections

  - Metabolic disorders (329)
  - Molecular genetics (1254)
  - Diabetes (105)
  - Clinical diagnostic tests (356)
  - Surgery (105)
  - Surgical diagnostic tests (105)
  - Genetic screening / counselling (886)
  - Liver disease (51)
  - JMG Online mutation reports (168)

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/